BR112018013323A2 - molécula de ácido nucleico, inibidor de expressão, medicamento, agente terapêutico, método para inibir expressão de um gene pró-renina ou um gene receptor pró-renina, e, uso de uma molécula de ácido nucleico. - Google Patents
molécula de ácido nucleico, inibidor de expressão, medicamento, agente terapêutico, método para inibir expressão de um gene pró-renina ou um gene receptor pró-renina, e, uso de uma molécula de ácido nucleico.Info
- Publication number
- BR112018013323A2 BR112018013323A2 BR112018013323-0A BR112018013323A BR112018013323A2 BR 112018013323 A2 BR112018013323 A2 BR 112018013323A2 BR 112018013323 A BR112018013323 A BR 112018013323A BR 112018013323 A2 BR112018013323 A2 BR 112018013323A2
- Authority
- BR
- Brazil
- Prior art keywords
- pro
- renin
- gene
- nucleic acid
- acid molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
a invenção provê uma molécula de ácido nucleico de filamento único para inibir a expressão de um gene pró-renina ou um gene receptor pró-renina, em que a molécula de ácido nucleico é distinguida pelo fato de que a molécula de ácido nucleico compreende apenas uma região (x), uma estrutura ligante (lx), e uma região (xc); a estrutura ligante (lx) tem uma estrutura não nucleotídica incluindo um esqueleto pirrolidina e/ou um esqueleto piperidina; e a região (x) e/ou a região (xc) inclui uma sequência de bases de pelo menos 18 bases consecutivas dentre qualquer uma de as sequências que inibem a expressão do gene pró-renina representadas pelas seq id nos: 1 a 5 e sequências que inibem a expressão do gene receptor pró-renina representadas pelas seq id nos: 6 a 11.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-257713 | 2015-12-29 | ||
JP2015257713 | 2015-12-29 | ||
PCT/JP2016/089216 WO2017115872A1 (ja) | 2015-12-29 | 2016-12-29 | プロレニン遺伝子またはプロレニン受容体遺伝子の発現を抑制する一本鎖核酸分子およびその用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018013323A2 true BR112018013323A2 (pt) | 2018-12-11 |
Family
ID=59225198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018013323-0A BR112018013323A2 (pt) | 2015-12-29 | 2016-12-29 | molécula de ácido nucleico, inibidor de expressão, medicamento, agente terapêutico, método para inibir expressão de um gene pró-renina ou um gene receptor pró-renina, e, uso de uma molécula de ácido nucleico. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20190010503A1 (pt) |
EP (1) | EP3399037A4 (pt) |
JP (2) | JP6634095B2 (pt) |
KR (1) | KR102116922B1 (pt) |
CN (1) | CN108473988A (pt) |
AU (1) | AU2016382055C1 (pt) |
BR (1) | BR112018013323A2 (pt) |
CA (1) | CA3009769C (pt) |
HK (1) | HK1259060A1 (pt) |
MX (1) | MX2018008086A (pt) |
RU (1) | RU2718984C2 (pt) |
WO (1) | WO2017115872A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102357337B1 (ko) | 2013-12-27 | 2022-01-28 | 가부시키가이샤 보낙 | 유전자 발현 제어를 위한 인공 매치형 miRNA 및 그 용도 |
ES2872527T3 (es) | 2014-12-27 | 2021-11-02 | Bonac Corp | miARN natural para controlar la expresión génica y uso del mismo |
ES2926369T3 (es) | 2015-03-27 | 2022-10-25 | Bonac Corp | Molécula de ácido nucleico monocatenario que tiene función de suministro y capacidad de control de la expresión génica |
CN108004310B (zh) * | 2017-12-13 | 2022-04-08 | 深圳大学 | 肾素(原)受体(p)rr基因及其抑制剂的应用 |
JP7250931B2 (ja) | 2019-08-06 | 2023-04-03 | 日本曹達株式会社 | 金属張積層板用樹脂組成物、プリプレグ、及び金属張積層板 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
WO2005037317A2 (en) * | 2003-10-17 | 2005-04-28 | Cornell Research Foundation, Inc. | Mast cell-derived renin |
AU2005276245C1 (en) * | 2004-08-23 | 2015-02-26 | Sylentis S.A.U. | Treatment of eye disorders characterized by an elevated introacular pressure by siRNAs |
EP1890152A1 (en) * | 2006-08-14 | 2008-02-20 | Charite Universitätsmedizin-Berlin | Determination of renin/prorenin receptor activity |
WO2009143619A1 (en) * | 2008-05-27 | 2009-12-03 | Chum | Methods of treating or preventing obesity and obesity-related hypertension |
EP2933333B1 (en) * | 2010-07-08 | 2018-02-21 | Bonac Corporation | Single-strand nucleic acid molecule for controlling gene expression |
JP4965745B2 (ja) * | 2010-08-03 | 2012-07-04 | 株式会社ボナック | 含窒素脂環式骨格を有する一本鎖核酸分子 |
TWI586684B (zh) | 2011-08-25 | 2017-06-11 | Bonac Corp | Preparation of thioethers |
JP2013055913A (ja) * | 2011-09-09 | 2013-03-28 | Bonac Corp | 遺伝子発現制御のための一本鎖rna分子 |
WO2015093495A1 (ja) * | 2013-12-16 | 2015-06-25 | 株式会社ボナック | TGF-β1遺伝子発現制御のための一本鎖核酸分子 |
CN112301031A (zh) * | 2014-05-22 | 2021-02-02 | 阿尔尼拉姆医药品有限公司 | 血管紧张素原(AGT)iRNA组合物及其使用方法 |
-
2016
- 2016-12-29 JP JP2017559254A patent/JP6634095B2/ja not_active Expired - Fee Related
- 2016-12-29 CA CA3009769A patent/CA3009769C/en not_active Expired - Fee Related
- 2016-12-29 MX MX2018008086A patent/MX2018008086A/es unknown
- 2016-12-29 US US16/065,779 patent/US20190010503A1/en not_active Abandoned
- 2016-12-29 AU AU2016382055A patent/AU2016382055C1/en not_active Ceased
- 2016-12-29 CN CN201680077351.XA patent/CN108473988A/zh active Pending
- 2016-12-29 BR BR112018013323-0A patent/BR112018013323A2/pt not_active IP Right Cessation
- 2016-12-29 EP EP16881846.6A patent/EP3399037A4/en not_active Withdrawn
- 2016-12-29 KR KR1020187019572A patent/KR102116922B1/ko active IP Right Grant
- 2016-12-29 WO PCT/JP2016/089216 patent/WO2017115872A1/ja active Application Filing
- 2016-12-29 RU RU2018127481A patent/RU2718984C2/ru active
-
2019
- 2019-01-29 HK HK19101560.7A patent/HK1259060A1/zh unknown
- 2019-11-05 JP JP2019201036A patent/JP6882741B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JPWO2017115872A1 (ja) | 2018-08-30 |
WO2017115872A1 (ja) | 2017-07-06 |
EP3399037A4 (en) | 2019-05-29 |
RU2018127481A (ru) | 2020-01-31 |
RU2018127481A3 (pt) | 2020-01-31 |
CN108473988A (zh) | 2018-08-31 |
AU2016382055B2 (en) | 2019-12-05 |
US20190010503A1 (en) | 2019-01-10 |
AU2016382055A1 (en) | 2018-07-26 |
JP2020031657A (ja) | 2020-03-05 |
JP6634095B2 (ja) | 2020-01-22 |
HK1259060A1 (zh) | 2019-11-22 |
KR20180086263A (ko) | 2018-07-30 |
MX2018008086A (es) | 2018-11-12 |
CA3009769A1 (en) | 2017-07-06 |
EP3399037A1 (en) | 2018-11-07 |
CA3009769C (en) | 2021-01-12 |
KR102116922B1 (ko) | 2020-06-01 |
JP6882741B2 (ja) | 2021-06-02 |
RU2718984C2 (ru) | 2020-04-15 |
AU2016382055C1 (en) | 2020-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018013323A2 (pt) | molécula de ácido nucleico, inibidor de expressão, medicamento, agente terapêutico, método para inibir expressão de um gene pró-renina ou um gene receptor pró-renina, e, uso de uma molécula de ácido nucleico. | |
EA201690526A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
EA201791417A1 (ru) | Супрессия гена гентингтина, индуцированная рнк-интерференцией | |
NZ748150A (en) | Modified nucleotide linkers | |
CO2018008173A2 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
CY1121395T1 (el) | Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6 | |
MX2017008184A (es) | Nucleosidos sustituidos, nucleotidos y analogos de estos. | |
MX2017010857A (es) | Metodos para la cobertura de secuencia de acidos nucleicos seleccionados como diana. | |
MX2018000511A (es) | Derivados de fenoximetilo. | |
EA201492122A1 (ru) | Композиции и способы для модулирования экспрессии utrn | |
EA201492116A1 (ru) | Композиции и способы для модулирования экспрессии mecp2 | |
BR112016010165A2 (pt) | composições de nucleotídeos modificados de citidina-5-carboxamida e métodos relacionados às mesmas | |
EA201691794A1 (ru) | Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) | |
EA201692537A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
PH12015501423A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
EA201492123A1 (ru) | Композиции и способы для модулирования экспрессии семейства генов smn | |
UA113980C2 (uk) | Заміщені нуклеозиди, нуклеотиди і їх аналоги | |
TW201613612A (en) | Substituted nucleosides, nucleotides and analogs thereof | |
CY1124929T1 (el) | 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινες ως ρυθμιστες του gpr139 | |
EA201492120A1 (ru) | Композиции и способы для модулирования экспрессии atp2a2 | |
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
EA201500659A1 (ru) | Ацетилтрансферазы и их применение для получения каротиноидов | |
BR112014030473A2 (pt) | novo diazaespirocicloalcano e azaespirocicloalcano | |
EA201492118A1 (ru) | Композиции и способы для модулирования экспрессии pten | |
EA201492117A1 (ru) | Композиции и способы для модулирования экспрессии bdnf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2703 DE 25/10/2022. |